Aquestive Therapeutics, Inc. Fair Value Adjustment of Warrants
Aquestive Therapeutics, Inc. (AQST) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-11.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2020-03-11
- Aquestive Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2019-12-31 was $0.00.
- Aquestive Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- Aquestive Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- Aquestive Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2019-03-31 was $0.00.
- Aquestive Therapeutics, Inc. fair value adjustment of warrants for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Aquestive Therapeutics, Inc. fair value adjustment of warrants for fiscal 2018 was $5.28M, a 369.99% increase from fiscal 2017.
- Aquestive Therapeutics, Inc. fair value adjustment of warrants for fiscal 2017 was $1.12M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 derived: sum of 3 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-03-11 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | $0.00 derived: sum of 3 quarters · filed 2020-03-11 | $4.12M derived: sum of 4 quarters · filed 2020-03-11 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $4.12M derived: sum of 3 quarters · filed 2020-03-11 | $5.97M derived: sum of 4 quarters · filed 2020-03-11 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $4.12M derived: sum of 2 quarters · filed 2020-03-11 | $5.97M derived: sum of 3 quarters · filed 2020-03-11 | $5.28M 10-K · filed 2020-03-11 |
| 2018-09-30 | $4.12M 10-Q · filed 2019-11-05 | $5.97M derived: sum of 2 quarters · filed 2019-11-05 | $5.28M 10-Q · filed 2019-11-05 | $6.09M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $1.86M 10-Q · filed 2019-08-06 | $1.16M 10-Q · filed 2019-08-06 | $1.98M derived: sum of 3 quarters · filed 2019-08-06 | $1.98M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | -$697.00K 10-Q · filed 2019-05-08 | $117.00K derived: sum of 2 quarters · filed 2019-05-08 | $117.00K derived: sum of 3 quarters · filed 2019-05-08 | $6.00K derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $814.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $814.00K derived: sum of 2 quarters · filed 2019-03-14 | $703.00K derived: sum of 3 quarters · filed 2019-03-14 | $1.12M 10-K · filed 2019-03-14 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-06 | -$111.00K derived: sum of 2 quarters · filed 2018-11-06 | $309.00K 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$111.00K 10-Q · filed 2018-09-04 | $309.00K 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |